12:00 AM
 | 
Jul 07, 2003
 |  BioCentury  |  Finance

2Q Approvals

2Q Approvals

Company Approvals
AstraZeneca (LSE:AZN; AZN) FDA approves Iressa gefitinib as third-line monotherapy in advanced non-small cell lung cancer
BioMarin (BMRN; SWX:BMRN)/Genzyme (GENZ) FDA and EMEA approve Aldurazyme laronidase to...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >